• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

6-Bromoindirubin-3 ′-Oxime (6BIO) Suppresses the mTOR Pathway, Promotes Autophagy, and Exerts Anti-aging Effects in Rodent Liver
In this study, we aimed to investigate the anti-aging effect, and molecular mechanism, of the novel anti-aging drug 6BIO on naturally aged mouse liver. Rapamycin, a well-known promising anti-aging drug that delays aging through mTOR-dependent autophagy (Zhou and Ye, 2018), was used as the positive control in the study. To our knowledge, this is the first study to demonstrate the effects of 6BIO treatment in models of natural aging. Our results indicated that 6BIO ameliorates the decline of liver function with age, including lipid metabolism disorder, and attenuates hepatocyte senescence in aged mice, as revealed by altera...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

Dizziness from standing up may mean higher risk of dementia
People with orthostatic hypotension in middle age had 54% higher risk of developing dementia Related items fromOnMedica Hypertension raises risk of mitral regurgitation Dementia and stroke funding remains too low, say experts Stroke can often be avoided, claims study Adding insulin to metformin linked to higher mortality Stroke rates rocket in younger men and women
Source: OnMedica Latest News - July 26, 2018 Category: UK Health Source Type: news

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
This study is registered with ClinicalTrials.gov, number NCT00700856. Findings Between Sept 18, 2008, and Jan 15, 2014, 3028 patients were randomly assigned and included in the analyses. 1535 were assigned to pioglitazone and 1493 to sulfonylureas (glibenclamide 24 [2%], glimepiride 723 [48%], gliclazide 745 [50%]). At baseline, 335 (11%) participants had a previous cardiovascular event. The study was stopped early on the basis of a futility analysis after a median follow-up of 57·3 months. The primary outcome occurred in 105 patients (1·5 per 100 person-years) who were given pioglitazone and 108 (1·5 per 100 person-yea...
Source: The Lancet Diabetes and Endocrinology - September 14, 2017 Category: Endocrinology Source Type: research

Stroke risk in treatment of type 2 diabetes in China: a 7 year retrospective cohort study
Publication date: November 2016 Source:The Lancet Diabetes & Endocrinology, Volume 4, Supplement 1 Author(s): Rui Liu, Qing Wang, Vivian Szeto, Andrew Barszczyk, Tianru Jin, Edoardo Mannucci, Hong-Shuo Sun, Zhong-Ping Feng Background Diabetes and stroke are leading causes of death and disability, and major public health concerns in China, which accounts for 25% of patients with diabetes worldwide. Type 2 diabetes is an independent risk factor for cerebral ischaemia and accounts for about 20% of stroke cases. We previously showed that KATP channel activation provides neuroprotection against cerebral ischaemia and t...
Source: The Lancet Diabetes and Endocrinology - November 17, 2016 Category: Endocrinology Source Type: research